[
    {
        "title": "Beckman Coulter, Siemens Healthineers, Abbott, Others Gain 510(k) Clearances in March",
        "summary": "<p><span><span><span>The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.</span></span></span></p>",
        "link": "https://www.360dx.com/regulatory-news-fda-approvals/beckman-coulter-siemens-healthineers-abbott-others-gain-510k",
        "published": "Wed, 16 Apr 2025 14:35:26 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda",
        "summary": "<p><span><span><span>The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/agilent-gains-ivdr-certification-expanded-use-cdx-assay-keytruda",
        "published": "Thu, 17 Apr 2025 10:04:09 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "EntroGen Colorectal Cancer RAS Mutation Detection Test Nabs CMS Coverage",
        "summary": "<p><span><span><span>The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab). </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/entrogen-colorectal-cancer-ras-mutation-detection-test-nabs-cms-coverage",
        "published": "Mon, 28 Apr 2025 14:27:37 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "EntroGen Colorectal Cancer RAS Mutation Detection Test Nabs CMS Coverage",
        "summary": "<p><span><span><span>The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab). </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/entrogen-colorectal-cancer-ras-mutation-detection-test-nabs-cms-coverage",
        "published": "Mon, 28 Apr 2025 14:27:37 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/medtech/roche-receives-fda-breakthrough-label-ai-powered-lung-cancer-companion-diagnostic-test\" hreflang=\"en\">Roche receives FDA breakthrough label for AI-powered lung cancer companion diagnostic test</a>",
        "summary": "Roche\u2019s companion diagnostic aims to identify non-small cell lung cancer patients who may benefit from Datroway, an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo.",
        "link": "https://www.fiercebiotech.com/medtech/roche-receives-fda-breakthrough-label-ai-powered-lung-cancer-companion-diagnostic-test",
        "published": "Apr 29, 2025 12:05pm",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "FDA Approves Roche Lung Cancer CDx Assay for Use with AbbVie's Emrelis",
        "summary": "<p><span><span><span>The test detects the MET protein that is over-expressed in some patients with non-squamous non-small cell lung cancer. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/fda-approves-roche-lung-cancer-cdx-assay-use-abbvies-emrelis",
        "published": "Wed, 14 May 2025 17:26:50 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Tempus AI, Verastem Partner to Develop CDx Assay for Ovarian Cancer Combination Treatment",
        "summary": "<p><span><span><span>Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase III RAMP-301 clinical trial. </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/tempus-ai-verastem-partner-develop-cdx-assay-ovarian-cancer-combination-treatment",
        "published": "Tue, 20 May 2025 09:31:24 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Tempus AI, Verastem Partner to Develop CDx Assay for Ovarian Cancer Combination Treatment",
        "summary": "<p><span><span><span>Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase III RAMP-301 clinical trial. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/tempus-ai-verastem-partner-develop-cdx-assay-ovarian-cancer-combination-treatment",
        "published": "Tue, 20 May 2025 09:31:24 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "ODAC votes for Darzalex in smoldering multiple myeloma",
        "summary": "<div class=\"title-top\">MAY 23, 2025 | 2:42 PM PDT | BIOCENTURY | DATA BYTE</div><div class=\"title-bottom\">ODAC VOTES FOR DARZALEX IN SMOLDERING MULTIPLE MYELOMA</div><div class=\"byline\">BY </div>Three other products get negative committee outcomes<a href=\"https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma\">https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma</a><a href=\"https://www.biocentury.com/copyright\">\u00a9 2025 BioCentury Inc. All Rights Reserved</a>",
        "link": "https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma",
        "published": "Fri, 23 May 2025 14:42:56 -0700",
        "keywords": [
            "smoldering multiple myeloma"
        ]
    },
    {
        "title": "Illumina to Offer Pillar Biosciences CDx Assay In Expanded Partnership",
        "summary": "<p><span><span><span>This summer, Illumina will begin offering its customers the <em>in vitro</em> diagnostic kit, which detects variants in 22 genes.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/illumina-offer-pillar-biosciences-cdx-assay-expanded-partnership",
        "published": "Wed, 28 May 2025 10:20:41 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Illumina to Offer Pillar Biosciences CDx Assay In Expanded Partnership",
        "summary": "<p><span><span><span>This summer, Illumina will begin offering its customers the <em>in vitro</em> diagnostic kit, which detects variants in 22 genes.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/illumina-offer-pillar-biosciences-cdx-assay-expanded-partnership",
        "published": "Wed, 28 May 2025 10:20:41 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Biocartis Gains IVDR Class C Certification for Lung Cancer CDx",
        "summary": "<p><span><span><span>The molecular diagnostics firm's Idylla EGFR Mutation Test is used to guide targeted therapies for patients with non-small cell lung cancer.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/biocartis-gains-ivdr-class-c-certification-lung-cancer-cdx",
        "published": "Mon, 02 Jun 2025 09:55:11 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Biocartis Gains IVDR Class C Certification for Lung Cancer CDx",
        "summary": "<p><span><span><span>The molecular diagnostics firm's Idylla EGFR Mutation Test is used to guide targeted therapies for patients with non-small cell lung cancer.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/biocartis-gains-ivdr-class-c-certification-lung-cancer-cdx",
        "published": "Mon, 02 Jun 2025 09:55:11 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/medtech/asco-guardant-blood-test-guides-breast-cancer-therapy-switches-extending-survival-az-backed\" hreflang=\"en\">ASCO: Guardant blood test guides breast cancer therapy switches, extending survival in AZ-backed study</a>",
        "summary": "A new study sponsored by AstraZeneca suggests that using the Guardant360 CDx test to spot early signs of therapy resistance in advanced breast cancer patients and inform a treatment change could slash the risk of disease progression or death by half.",
        "link": "https://www.fiercebiotech.com/medtech/asco-guardant-blood-test-guides-breast-cancer-therapy-switches-extending-survival-az-backed",
        "published": "Jun 2, 2025 4:21pm",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Research shows new treatment could delay cancer progression in patients with high-risk smoldering multiple myeloma",
        "summary": "A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.",
        "link": "https://www.sciencedaily.com/releases/2024/12/241210163409.htm",
        "published": "Tue, 10 Dec 2024 16:34:09 EST",
        "keywords": [
            "smoldering multiple myeloma"
        ]
    },
    {
        "title": "Obesity linked to detection of blood cancer precursor",
        "summary": "Individuals with obesity are more likely to have monoclonal gammopathy of undetermined significance (MGUS), a benign blood condition that often precedes multiple myeloma, according to new research.",
        "link": "https://www.sciencedaily.com/releases/2024/01/240114202019.htm",
        "published": "Sun, 14 Jan 2024 20:20:19 EST",
        "keywords": [
            "MGUS"
        ]
    },
    {
        "title": "Lenalidomide may delay onset of myeloma-related bone, organ damage",
        "summary": "The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage.",
        "link": "https://www.sciencedaily.com/releases/2019/10/191028104212.htm",
        "published": "Mon, 28 Oct 2019 10:42:12 EDT",
        "keywords": [
            "smoldering multiple myeloma"
        ]
    },
    {
        "title": "Blood cancer precursor found in 9/11 firefighters",
        "summary": "A new study reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma.",
        "link": "https://www.sciencedaily.com/releases/2018/04/180426141507.htm",
        "published": "Thu, 26 Apr 2018 14:15:07 EDT",
        "keywords": [
            "MGUS"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/biotech/cullinan-pens-700m-pact-bcma-bispecific-pair-another-autoimmune-t-cell-engager\" hreflang=\"en\">Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T-cell engager</a>",
        "summary": "Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T-cell engager that the biotech plans to pair with its existing CD19 candidate.",
        "link": "https://www.fiercebiotech.com/biotech/cullinan-pens-700m-pact-bcma-bispecific-pair-another-autoimmune-t-cell-engager",
        "published": "Jun 5, 2025 4:40am",
        "keywords": [
            "BCMA"
        ]
    },
    {
        "title": "Randox Laboratories Gains FDA De Novo Clearance for Hemophilia CDx",
        "summary": "<p><span><span><span>The Randox ConcizuTrace ELISA is used to determine the concentration in blood of Novo Nordisk's Alhemo (concizumab-mtci) to aid dose adjustments.</span></span></span></p>",
        "link": "https://www.360dx.com/immunoassays/randox-laboratories-gains-fda-de-novo-clearance-hemophilia-cdx",
        "published": "Thu, 05 Jun 2025 09:41:07 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/medtech/cancer-tester-caris-life-sciences-go-public-400m-nasdaq-ipo\" hreflang=\"en\">Cancer tester Caris Life Sciences to go public in $400M Nasdaq IPO</a>",
        "summary": "Caris recently began rolling out its MI Cancer Seek companion diagnostic test for genomic tumor profiling.",
        "link": "https://www.fiercebiotech.com/medtech/cancer-tester-caris-life-sciences-go-public-400m-nasdaq-ipo",
        "published": "Jun 9, 2025 10:17am",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Qiagen, Incyte Partner to Develop Companion Diagnostics for CALR-Mutant, Other Blood Cancers",
        "summary": "<p><span><span><span>Qiagen will develop and validate a next-generation sequencing assay, initially targeting the CALR gene, to guide treatment for myeloproliferative neoplasms.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/qiagen-incyte-partner-develop-companion-diagnostics-calr-mutant-other-blood-cancers",
        "published": "Mon, 16 Jun 2025 10:44:45 EDT",
        "keywords": [
            "companion diagnostics"
        ]
    },
    {
        "title": "Qiagen, Incyte Partner to Develop Companion Diagnostics for CALR-Mutant, Other Blood Cancers",
        "summary": "<p><span><span><span>Qiagen will develop and validate a next-generation sequencing assay, initially targeting the CALR gene, to guide treatment for myeloproliferative neoplasms.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/qiagen-incyte-partner-develop-companion-diagnostics-calr-mutant-other-blood-cancers",
        "published": "Mon, 16 Jun 2025 10:44:45 EDT",
        "keywords": [
            "companion diagnostics"
        ]
    },
    {
        "title": "Illumina\u2019s buy of Somalogic could be tipping point for multiomics: Deals Report",
        "summary": "<div class=\"title-top\">JUN 23, 2025 | 6:44 PM PDT | BIOCENTURY | DEALS</div><div class=\"title-bottom\">ILLUMINA\u2019S BUY OF SOMALOGIC COULD BE TIPPING POINT FOR MULTIOMICS: DEALS REPORT</div><div class=\"byline\">BY </div>Plus: A second deal this month for a BCMA bispecific for autoimmunity, a priority review voucher sale, and more\u00a0<a href=\"https://www.biocentury.com/article/656269/illumina-s-buy-of-somalogic-could-be-tipping-point-for-multiomics-deals-report\">https://www.biocentury.com/article/656269/illumina-s-buy-of-somalogic-could-be-tipping-point-for-multiomics-deals-report</a><a href=\"https://www.biocentury.com/copyright\">\u00a9 2025 BioCentury Inc. All Rights Reserved</a>",
        "link": "https://www.biocentury.com/article/656269/illumina-s-buy-of-somalogic-could-be-tipping-point-for-multiomics-deals-report",
        "published": "Mon, 23 Jun 2025 18:44:19 -0700",
        "keywords": [
            "BCMA"
        ]
    },
    {
        "title": "MetasTx Secures $500K NCI Grant to Develop Metastatic Prostate Cancer CDx Test",
        "summary": "<p>The company hopes to complete proof of principle for a companion diagnostic to identify patients with PCa who are likely to need aggressive treatment.</p>",
        "link": "https://www.genomeweb.com/cancer/metastx-secures-500k-nci-grant-develop-metastatic-prostate-cancer-cdx-test",
        "published": "Wed, 25 Jun 2025 10:17:04 EDT",
        "keywords": [
            "CDx",
            "companion diagnostic"
        ]
    },
    {
        "title": "MetasTx Secures $500K NCI Grant to Develop Metastatic Prostate Cancer CDx Test",
        "summary": "<p>The company hopes to complete proof of principle for a companion diagnostic to identify patients with PCa who are likely to need aggressive treatment.</p>",
        "link": "https://www.360dx.com/cancer/metastx-secures-500k-nci-grant-develop-metastatic-prostate-cancer-cdx-test",
        "published": "Wed, 25 Jun 2025 10:17:04 EDT",
        "keywords": [
            "CDx",
            "companion diagnostic"
        ]
    },
    {
        "title": "Qiagen Partnership Program Aims to Build out Clinical dPCR Menu",
        "summary": "<p><span><span><span>The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.</span></span></span></p>",
        "link": "https://www.genomeweb.com/molecular-diagnostics/qiagen-partnership-program-aims-build-out-clinical-dpcr-menu",
        "published": "Fri, 27 Jun 2025 10:42:37 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Qiagen Partnership Program Aims to Build out Clinical dPCR Menu",
        "summary": "<p><span><span><span>The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.</span></span></span></p>",
        "link": "https://www.360dx.com/molecular-diagnostics/qiagen-partnership-program-aims-build-out-clinical-dpcr-menu",
        "published": "Fri, 27 Jun 2025 10:42:37 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Thermo Fisher NGS Assay Gets FDA OK as CDx for Dizal's Zegfrovy and for Solid Tumor Profiling",
        "summary": "<p><span><span><span>The Oncomine Dx Express Test was approved as a CDx for Dizal's Zegfrovy to identify non-small cell lung cancer patients harboring EGFR exon 20 insertion mutations. </span></span></span></p>",
        "link": "https://www.genomeweb.com/sequencing/thermo-fisher-ngs-assay-gets-fda-ok-cdx-dizals-zegfrovy-and-solid-tumor-profiling",
        "published": "Thu, 03 Jul 2025 10:32:13 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Thermo Fisher NGS Assay Gets FDA OK as CDx for Dizal's Zegfrovy and for Solid Tumor Profiling",
        "summary": "<p><span><span><span>The Oncomine Dx Express Test was approved as a CDx for Dizal's Zegfrovy to identify non-small cell lung cancer patients harboring EGFR exon 20 insertion mutations. </span></span></span></p>",
        "link": "https://www.360dx.com/sequencing/thermo-fisher-ngs-assay-gets-fda-ok-cdx-dizals-zegfrovy-and-solid-tumor-profiling",
        "published": "Thu, 03 Jul 2025 10:32:13 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Thermo Fisher Nabs FDA Approval for NGS-Based CDx for Boehringer Ingelheim Lung Cancer Drug",
        "summary": "<p><span><span><span>The Oncomine Dx Target Test assesses if NSCLC patients harbor\u00a0HER2 tyrosine kinase domain-activating mutations, making them eligible for Boehringer's Hernexeos.</span></span></span></p>",
        "link": "https://www.genomeweb.com/sequencing/thermo-fisher-nabs-fda-approval-ngs-based-cdx-boehringer-ingelheim-lung-cancer-drug",
        "published": "Mon, 11 Aug 2025 10:04:39 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Thermo Fisher Nabs FDA Approval for NGS-Based CDx for Boehringer Ingelheim Lung Cancer Drug",
        "summary": "<p><span><span><span>The Oncomine Dx Target Test assesses if NSCLC patients harbor\u00a0HER2 tyrosine kinase domain-activating mutations, making them eligible for Boehringer's Hernexeos.</span></span></span></p>",
        "link": "https://www.360dx.com/sequencing/thermo-fisher-nabs-fda-approval-ngs-based-cdx-boehringer-ingelheim-lung-cancer-drug",
        "published": "Mon, 11 Aug 2025 10:04:39 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Thermo Fisher Nabs FDA Approval for NGS-Based CDx for Boehringer Ingelheim Lung Cancer Drug",
        "summary": "<p><span><span><span>The Oncomine Dx Target Test assesses if NSCLC patients harbor\u00a0HER2 tyrosine kinase domain-activating mutations, making them eligible for Boehringer's Hernexeos.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/thermo-fisher-nabs-fda-approval-ngs-based-cdx-boehringer-ingelheim-lung-cancer-drug",
        "published": "Mon, 11 Aug 2025 10:04:39 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Thermo Fisher Nabs FDA Approval for NGS-Based CDx for Boehringer Ingelheim Lung Cancer Drug",
        "summary": "<p><span><span><span>The Oncomine Dx Target Test assesses if NSCLC patients harbor\u00a0HER2 tyrosine kinase domain-activating mutations, making them eligible for Boehringer's Hernexeos.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/thermo-fisher-nabs-fda-approval-ngs-based-cdx-boehringer-ingelheim-lung-cancer-drug",
        "published": "Mon, 11 Aug 2025 10:04:39 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "FDA Approves Agilent CDx Assay for Use With Bristol Myers Squibb Immunotherapies",
        "summary": "<p><span><span><span>The MMR IHC Panel PharmDx (Dako Omnis) is used to identify loss of function in mismatch repair proteins and inform the treatment of colorectal cancer patients.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/fda-approves-agilent-cdx-assay-use-bristol-myers-squibb-immunotherapies",
        "published": "Wed, 20 Aug 2025 09:41:52 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Caris Life Sciences Eyes Wider Clinical Adoption of Tests With New Validation Data",
        "summary": "<p>The MI Cancer Seek assay performed equivalently to other FDA-approved tests in a recently published study, and the company is now working to add more CDx claims.</p>",
        "link": "https://www.genomeweb.com/cancer/caris-life-sciences-eyes-wider-clinical-adoption-tests-new-validation-data",
        "published": "Tue, 26 Aug 2025 14:01:15 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Caris Life Sciences Eyes Wider Clinical Adoption of Tests With New Validation Data",
        "summary": "<p>The MI Cancer Seek assay performed equivalently to other FDA-approved tests in a recently published study, and the company is now working to add more CDx claims.</p>",
        "link": "https://www.360dx.com/cancer/caris-life-sciences-eyes-wider-clinical-adoption-tests-new-validation-data",
        "published": "Tue, 26 Aug 2025 14:01:15 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Agilent Secures IVDR Class C Certification for Colorectal Cancer CDx",
        "summary": "<p><span><span><span>The MMR IHC Panel PharmDx (Dako Omnis) is used to determine eligibility for treatment with a combination of Bristol Myers Squibb immunotherapies.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/agilent-secures-ivdr-class-c-certification-colorectal-cancer-cdx",
        "published": "Tue, 02 Sep 2025 09:43:54 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Roche Nabs CE-IVDR Marking for HER2 CDx Assay for Breast, Biliary Tract Cancer",
        "summary": "<p><span><span><span>The test is approved to help assess HER2-ultralow status to identify breast cancer patients who may be eligible for treatment with Enhertu. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/roche-nabs-ce-ivdr-marking-her2-cdx-assay-breast-biliary-tract-cancer",
        "published": "Fri, 05 Sep 2025 09:46:02 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Biocartis Gets FDA Approval for MSI Companion Diagnostic",
        "summary": "<p><span><span>The fully automated, cartridge-based assay is intended to aid oncologists in identifying colorectal cancer patients eligible for immunotherapy treatment.</span></span></p>\n\n<p>\u00a0</p>",
        "link": "https://www.genomeweb.com/cancer/biocartis-gets-fda-approval-msi-companion-diagnostic",
        "published": "Mon, 15 Sep 2025 10:45:05 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Biocartis Gets FDA Approval for MSI Companion Diagnostic",
        "summary": "<p><span><span>The fully automated, cartridge-based assay is intended to aid oncologists in identifying colorectal cancer patients eligible for immunotherapy treatment.</span></span></p>\n\n<p>\u00a0</p>",
        "link": "https://www.360dx.com/cancer/biocartis-gets-fda-approval-msi-companion-diagnostic",
        "published": "Mon, 15 Sep 2025 10:45:05 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "AmoyDx Lung Cancer Panel Nabs Japanese Approval as CDx for Non-Small Cell Lung Cancer Drug Ibtrozi",
        "summary": "<p><span><span><span>The approval applies to patients with locally advanced or metastatic non-small cell lung cancer with ROS1 gene fusion. </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/amoydx-lung-cancer-panel-nabs-japanese-approval-cdx-non-small-cell-lung-cancer-drug-ibtrozi",
        "published": "Fri, 19 Sep 2025 10:19:48 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "AmoyDx Lung Cancer Panel Nabs Japanese Approval as CDx for Non-Small Cell Lung Cancer Drug Ibtrozi",
        "summary": "<p><span><span><span>The approval applies to patients with locally advanced or metastatic non-small cell lung cancer with ROS1 gene fusion. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/amoydx-lung-cancer-panel-nabs-japanese-approval-cdx-non-small-cell-lung-cancer-drug-ibtrozi",
        "published": "Fri, 19 Sep 2025 10:19:48 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Elranatamab-Based Triplet Effective in Transplant-Ineligible Myeloma",
        "summary": "<img src=\"https://clf1.medpagetoday.com/media/images/117xxx/117536.jpg\" /> (MedPage Today) -- TORONTO  --  A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab (Elrexfio) was associated with high response rates and manageable toxicity in newly diagnosed, transplant...",
        "link": "https://www.medpagetoday.com/meetingcoverage/ims/117536",
        "published": "Thu, 18 Sep 2025 17:03:51 -0400",
        "keywords": [
            "BCMA"
        ]
    },
    {
        "title": "Linvoseltamab Promising in High-Risk Smoldering Multiple Myeloma",
        "summary": "<img src=\"https://clf1.medpagetoday.com/media/images/117xxx/117570.jpg\" /> (MedPage Today) -- TORONTO  --  Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data.\nWith a median follow-up of 3.9 months among 19 evaluable...",
        "link": "https://www.medpagetoday.com/meetingcoverage/ims/117570",
        "published": "Sat, 20 Sep 2025 14:53:42 -0400",
        "keywords": [
            "smoldering multiple myeloma"
        ]
    },
    {
        "title": "OGT Assay Nabs FDA Authorization as CDx for Syndax's Revuforj in Acute Leukemia",
        "summary": "<p><span><span><span>The CytoCell KMT2A Breakapart FISH Probe Kit PDx detects clinically relevant rearrangements that occur in patients with acute leukemia.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/ogt-assay-nabs-fda-authorization-cdx-syndaxs-revuforj-acute-leukemia",
        "published": "Mon, 22 Sep 2025 10:17:30 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Agilent Technologies, Lunit Partner for Cancer CDx Development",
        "summary": "<p><span><span><span>The companies will initially focus on the development of companion diagnostics that can be used in research and clinical trials in collaborations with pharma companies.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/agilent-technologies-lunit-partner-cancer-cdx-development",
        "published": "Mon, 22 Sep 2025 10:32:18 EDT",
        "keywords": [
            "CDx",
            "companion diagnostics"
        ]
    },
    {
        "title": "OGT Assay Nabs FDA Authorization as CDx for Syndax's Revuforj in Acute Leukemia",
        "summary": "<p><span><span><span>The CytoCell KMT2A Breakapart FISH Probe Kit PDx detects clinically relevant rearrangements that occur in patients with acute leukemia.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/ogt-assay-nabs-fda-authorization-cdx-syndaxs-revuforj-acute-leukemia",
        "published": "Mon, 22 Sep 2025 10:17:30 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Myriad Genetics, Sophia Genetics to Collaborate on Cancer Liquid Biopsy Companion Diagnostic",
        "summary": "<p>Myriad will pursue US regulatory submissions of the assay, while Sophia will manage submissions elsewhere in the world.</p>",
        "link": "https://www.genomeweb.com/cancer/myriad-genetics-sophia-genetics-collaborate-cancer-liquid-biopsy-companion-diagnostic",
        "published": "Tue, 23 Sep 2025 10:17:07 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Myriad Genetics, Sophia Genetics to Collaborate on Cancer Liquid Biopsy Companion Diagnostic",
        "summary": "<p>Myriad will pursue US regulatory submissions of the assay, while Sophia will manage submissions elsewhere in the world.</p>",
        "link": "https://www.360dx.com/cancer/myriad-genetics-sophia-genetics-collaborate-cancer-liquid-biopsy-companion-diagnostic",
        "published": "Tue, 23 Sep 2025 10:17:07 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Burning Rock's Sequencing Test Approved in Japan as a CDx for Truqap in Breast Cancer",
        "summary": "<p><span><span>Japanese patients with HER2-negative, hormone receptor-positive advanced breast cancer can now receive testing to guide the use of AstraZeneca's\u00a0AKT inhibitor.</span></span></p>",
        "link": "https://www.genomeweb.com/cancer/burning-rocks-sequencing-test-approved-japan-cdx-truqap-breast-cancer",
        "published": "Wed, 24 Sep 2025 10:38:39 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Burning Rock's Sequencing Test Approved in Japan as a CDx for Truqap in Breast Cancer",
        "summary": "<p><span><span>Japanese patients with HER2-negative, hormone receptor-positive advanced breast cancer can now receive testing to guide the use of AstraZeneca's\u00a0AKT inhibitor.</span></span></p>",
        "link": "https://www.360dx.com/cancer/burning-rocks-sequencing-test-approved-japan-cdx-truqap-breast-cancer",
        "published": "Wed, 24 Sep 2025 10:38:39 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Biocartis Positioning Idylla System for Sample-to-Answer Oncology CDx Tests",
        "summary": "<p><span><span><span>A new test to help select colorectal cancer therapy is the first in a menu of rapid cartridge-based tests the firm is planning to support cancer testing.</span></span></span></p>",
        "link": "https://www.genomeweb.com/companion-diagnostics/biocartis-positioning-idylla-system-sample-answer-oncology-cdx-tests",
        "published": "Fri, 26 Sep 2025 13:25:16 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Biocartis Positioning Idylla System for Sample-to-Answer Oncology CDx Tests",
        "summary": "<p><span><span><span>A new test to help select colorectal cancer therapy is the first in a menu of rapid cartridge-based tests the firm is planning to support cancer testing.</span></span></span></p>",
        "link": "https://www.360dx.com/companion-diagnostics/biocartis-positioning-idylla-system-sample-answer-oncology-cdx-tests",
        "published": "Fri, 26 Sep 2025 13:25:16 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Guardant Health Blood Test Gets FDA OK as CDx for Eli Lilly Breast Cancer Drug Inluriyo",
        "summary": "<p><span><span>It's the sixth companion diagnostic approval for the Guardant360 comprehensive genomic profiling assay, which is intended to support personalized cancer treatment.</span></span></p>",
        "link": "https://www.genomeweb.com/cancer/guardant-health-blood-test-gets-fda-ok-cdx-eli-lilly-breast-cancer-drug-inluriyo",
        "published": "Mon, 29 Sep 2025 10:27:35 EDT",
        "keywords": [
            "CDx",
            "companion diagnostic"
        ]
    },
    {
        "title": "Guardant Health Blood Test Gets FDA OK as CDx for Eli Lilly Breast Cancer Drug Inluriyo",
        "summary": "<p><span><span>It's the sixth companion diagnostic approval for the Guardant360 comprehensive genomic profiling assay, which is intended to support personalized cancer treatment.</span></span></p>",
        "link": "https://www.360dx.com/cancer/guardant-health-blood-test-gets-fda-ok-cdx-eli-lilly-breast-cancer-drug-inluriyo",
        "published": "Mon, 29 Sep 2025 10:27:35 EDT",
        "keywords": [
            "CDx",
            "companion diagnostic"
        ]
    },
    {
        "title": "Celebrating the 10th Anniversary of its PD-L1 CDx, Agilent Sets Sights on Next-Gen Diagnostic Tools",
        "summary": "<p><span><span><span>October marks the 10-year anniversary of the US Food and Drug Administration\u2019s approval of the first companion diagnostic test for a PD-L1 inhibitor. </span></span></span></p>",
        "link": "https://www.genomeweb.com/companion-diagnostics/celebrating-10th-anniversary-its-pd-l1-cdx-agilent-sets-sights-next-gen",
        "published": "Mon, 20 Oct 2025 09:04:34 EDT",
        "keywords": [
            "CDx",
            "companion diagnostic"
        ]
    },
    {
        "title": "Geneseeq Nabs China NMPA Approval for Pan-Solid Tumor Test as CDx for Roche's Rozlytrek",
        "summary": "<p><span><span><span>The company said the assay is China's first sequencing-based pan-solid tumor CDx test and the first approved assay for detecting NTRK1/2/3 gene fusions.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/geneseeq-nabs-china-nmpa-approval-pan-solid-tumor-test-cdx-roches-rozlytrek",
        "published": "Mon, 10 Nov 2025 10:49:56 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Geneseeq Nabs China NMPA Approval for Pan-Solid Tumor Test as CDx for Roche's Rozlytrek",
        "summary": "<p><span><span><span>The company said the assay is China's first sequencing-based pan-solid tumor CDx test and the first approved assay for detecting NTRK1/2/3 gene fusions.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/geneseeq-nabs-china-nmpa-approval-pan-solid-tumor-test-cdx-roches-rozlytrek",
        "published": "Mon, 10 Nov 2025 10:49:56 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Promega Receives FDA Approval for OncoMate MSI Dx Analysis System as Endometrial Cancer CDx",
        "summary": "<p><span><span><span><span><span><span>The test is meant to identify patients with microsatellite stable endometrial carcinoma who may benefit from treatment with Merck's Keytruda combined with Easai's Lenvima.</span></span></span></span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/promega-receives-fda-approval-oncomate-msi-dx-analysis-system-endometrial-cancer-cdx",
        "published": "Wed, 12 Nov 2025 09:26:51 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Promega Receives FDA Approval for OncoMate MSI Dx Analysis System as Endometrial Cancer CDx",
        "summary": "<p><span><span><span><span><span><span>The test is meant to identify patients with microsatellite stable endometrial carcinoma who may benefit from treatment with Merck's Keytruda combined with Easai's Lenvima.</span></span></span></span></span></span></p>",
        "link": "https://www.360dx.com/cancer/promega-receives-fda-approval-oncomate-msi-dx-analysis-system-endometrial-cancer-cdx",
        "published": "Wed, 12 Nov 2025 09:26:51 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/medtech/promega-msi-tech-wins-fda-approval-companion-diagnostic-keytruda-lenvima-combo-uterine\" hreflang=\"en\">Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer</a>",
        "summary": "Promega has scored an FDA green light for its microsatellite instability testing technology as a companion diagnostic for Merck and Eisai\u2019s Keytruda-Lenvima combination for patients with advanced endometrial carcinoma.",
        "link": "https://www.fiercebiotech.com/medtech/promega-msi-tech-wins-fda-approval-companion-diagnostic-keytruda-lenvima-combo-uterine",
        "published": "Nov 13, 2025 2:56am",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Thermo Fisher Receives FDA Approval for NGS-Based CDx for Bayer Lung Cancer Therapy",
        "summary": "<p><span><span><span>The test determines patients' eligibility for Hyrnuo, Bayer's new HER2-directed therapy that was approved by the FDA this week for treating non-small cell lung cancer. </span></span></span></p>",
        "link": "https://www.genomeweb.com/regulatory-news-fda-approvals/thermo-fisher-receives-fda-approval-ngs-based-cdx-bayer-lung-cancer",
        "published": "Thu, 20 Nov 2025 10:04:10 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Thermo Fisher Receives FDA Approval for NGS-Based CDx for Bayer Lung Cancer Therapy",
        "summary": "<p><span><span><span>The test determines patients' eligibility for Hyrnuo, Bayer's new HER2-directed therapy that was approved by the FDA this week for treating non-small cell lung cancer. </span></span></span></p>",
        "link": "https://www.360dx.com/regulatory-news-fda-approvals/thermo-fisher-receives-fda-approval-ngs-based-cdx-bayer-lung-cancer",
        "published": "Thu, 20 Nov 2025 10:04:10 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "FDA Proposes Reclassification of Companion Diagnostic Tests",
        "summary": "<p><span><span><span>The agency would down-classify nucleic acid-based tests for use with a corresponding approved therapy product to Class II devices from Class III.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/fda-proposes-reclassification-companion-diagnostic-tests",
        "published": "Wed, 26 Nov 2025 10:19:23 EST",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "FDA Proposes Reclassification of Companion Diagnostic Tests",
        "summary": "<p><span><span><span>The agency would down-classify nucleic acid-based tests for use with a corresponding approved therapy product to Class II devices from Class III.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/fda-proposes-reclassification-companion-diagnostic-tests",
        "published": "Wed, 26 Nov 2025 10:19:23 EST",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Top Five Articles on 360Dx Last Week: FDA Aims to Reclassify CDx Tests; Tempus Buying OneOme Assets; More",
        "summary": "<p><span><span>Last week, readers were most interested in a story about FDA's plan to reclassify some tests that now require PMAs to require only 510(k) clearance.</span></span></p>",
        "link": "https://www.360dx.com/business-news/top-five-articles-360dx-last-week-fda-aims-reclassify-cdx-tests-tempus-buying-oneome",
        "published": "Mon, 01 Dec 2025 00:42:13 EST",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "FDA Proposal to Reclassify CDx Assays May Broaden Opportunities for Dx Manufacturers, Experts Say",
        "summary": "<p><span><span><span>The agency proposed down-classifying companion diagnostic assays to Class II devices from Class III devices. </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/fda-proposal-reclassify-cdx-assays-may-broaden-opportunities-dx-manufacturers-experts-say",
        "published": "Thu, 11 Dec 2025 17:23:59 EST",
        "keywords": [
            "CDx",
            "companion diagnostic"
        ]
    },
    {
        "title": "FDA Proposal to Reclassify CDx Assays May Broaden Opportunities for Dx Manufacturers, Experts Say",
        "summary": "<p><span><span><span>The agency proposed down-classifying companion diagnostic assays to Class II devices from Class III devices. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/fda-proposal-reclassify-cdx-assays-may-broaden-opportunities-dx-manufacturers-experts-say",
        "published": "Thu, 11 Dec 2025 17:23:59 EST",
        "keywords": [
            "CDx",
            "companion diagnostic"
        ]
    }
]